Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
KCNQ1 3784 CHEMBL1907717 CHEMBL1907717 activator GuideToPharmacologyInteractions
KCNQ1 3784 CHEMBL298475 CHEMBL298475 channel blocker GuideToPharmacologyInteractions
KCNQ1 3784 CELECOXIB CHEMBL118 PharmGKB
KCNQ1 3784 INDOMETHACIN CHEMBL6 TdgClinicalTrial
KCNQ1 3784 TEDISAMIL CHEMBL113461 blocker ChemblInteractions
KCNQ1 3784 DALFAMPRIDINE CHEMBL284348 blocker ChemblInteractions
KCNQ1 3784 CHEMBL342375 CHEMBL342375 channel blocker GuideToPharmacologyInteractions
KCNQ1 3784 CHEMBL332826 CHEMBL332826 channel blocker GuideToPharmacologyInteractions
KCNQ1 3784 EZOGABINE CHEMBL41355 blocker TdgClinicalTrial, ChemblInteractions
KCNQ1 3784 TACROLIMUS CHEMBL269732 PharmGKB
KCNQ1 3784 AZIMILIDE CHEMBL123558 DrugBank 11573692, 11060832
KCNQ1 3784 MEFENAMIC ACID CHEMBL686 activator GuideToPharmacologyInteractions
KCNQ1 3784 NERISPIRDINE CHEMBL2107762 blocker ChemblInteractions, TTD
KCNQ1 3784 INDAPAMIDE CHEMBL406 inhibitor, blocker TdgClinicalTrial, TEND, DrugBank, TTD 11752352, 11804849, 11351021
KCNQ1 3784 BEPRIDIL CHEMBL1008 inhibitor TdgClinicalTrial, TEND, DrugBank 9765513, 14716203, 10860024
KCNQ1 3784 CHEMBL2070953 CHEMBL2070953 activator GuideToPharmacologyInteractions
KCNQ1 3784 NIFLUMIC ACID CHEMBL63323 activator GuideToPharmacologyInteractions
KCNQ1 3784 GUANIDINE HYDROCHLORIDE CHEMBL1200728 blocker ChemblInteractions
KCNQ1 3784 DOLASETRON CHEMBL2368925 NCI 11046096

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
KCNQ1 rs2237892 CT + TT repaglinide efficacy yes Patients with the CT and TT genotypes had a greater decrease in postprandial plasma glucose (PPG) levels between baseline and after 8 weeks of treatment, compared to those with the CC genotype. Genotypes CT + TT are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype CC. 22414228 981502876
KCNQ1 rs2237895 AC + CC repaglinide efficacy yes Patients with the AC and CC genotypes had a greater increase in postprandial serum insulin levels between baseline and after 8 weeks of treatment, compared to those with the AA genotype. Genotypes AC + CC are associated with increased response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype AA. 22414228 981502885
KCNQ1 rs163184 G sitagliptin efficacy no as measured by reduction in glycated hemoglobin over 6 months. "Variant rs163184 in KCNQ1 showed a tendency to association of the G allele with a smaller reduction in HbA1c levels by 0.161% per allele, although not reaching the nominal level of significance after adjustment for covariates." Allele G is associated with decreased clinical benefit to sitagliptin or vildagliptin in people with Diabetes Mellitus, Type 2 as compared to allele T. 32308134 1451128748
KCNQ1 rs2237897 CT + TT gliclazide efficacy yes Fasting plasma glucose (FPG) had a greater reduction in CT and TT subjects vs CC and a higher rate of treatment success was found in T carriers. Genotypes CT + TT are associated with increased response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to genotype CC. 26866747 1447945831
KCNQ1 rs2237897 T gliclazide efficacy no No difference in fasting plasma glucose (FPG) reduction and rate of treatment success. Allele T is not associated with response to gliclazide in people with Diabetes Mellitus, Type 2 as compared to allele C. 26866747 1447945867